Dendrite Acquires BuzzeoPDMA, Inc. as Part of Strategic Growth Initiative.

BEDMINSTER, N.J. -- Acquisition Extends Depth and Breadth of Dendrite's First Source Sample(TM) Solution and Positions Dendrite as the Leading Provider of Compliance-Based Solutions and Services in the Life Sciences Industry

Dendrite International, Inc. (NASDAQ:DRTE) a leading provider of marketing, sales, clinical and compliance solutions for the life sciences industry, today announced that it has completed the acquisition of BuzzeoPDMA, Inc., a leading provider of compliance and auditing outsourcing services to the life sciences industry. The acquisition creates the industry's most complete sample and compliance management solution, providing life sciences companies with a single streamlined source for ensuring regulatory compliance. BuzzeoPDMA(TM), a long time strategic partner to Dendrite, will retain its name and senior management structure: Ronald W. Buzzeo, R.Ph. as Chief Regulatory Officer; and William E. Buzzeo as Vice President and General Manager.

"BuzzeoPDMA has provided specialized consulting and compliance services to a growing number of pharmaceutical and healthcare customers for more than a decade, building a strong reputation for quality and excellence," said Dendrite Chairman and CEO John Bailye. "This acquisition is part of our strategy to provide the industry's most comprehensive compliance management solutions to our customers."

The acquisition enhances Dendrite's premiere First Source Sample(TM) program, a comprehensive solution that manages the entire lifecycle of drug sample promotion. Drug sample promotion has been particularly strong in categories where competition has intensified, spurred by new drug launches as well as drugs being withdrawn from the market. BuzzeoPDMA's proven consulting and compliance services add a new dimension to First Source Sample and initiates a new offering, First Source Compliance. This streamlined, single-provider approach to sample and compliance management solutions is designed to help ensure comprehensive compliance with the policies of the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA), and with the regulatory requirements of the Prescription Drug Marketing Act (PDMA) and the Controlled Substances Act (CSA).

BuzzeoPDMA adds several new capabilities to Dendrite's solutions including federal and state consulting and compliance services, development of risk management programs, computer systems auditing and validation, learning services, inventories and audits of sales representatives, sample fulfillment, document scanning, reconciliation services, recall services, and sales representative close out services. BuzzeoPDMA also provides inspection services to the National Association of Boards of Pharmacy (NABP(R)) as part of their Verified-Accredited Wholesale Distributors (VAWD) program, designed to ensure the integrity of the US drug distribution system and to protect the public from counterfeit drugs.

First Source Sample customers can outsource a few areas or their entire sample administration. In addition, customers can now look to a single provider for FDA, DEA, and state regulatory compliance services through First Source Compliance. Since all First Source components are combined into one solution, customers can evolve their use of Dendrite's products and services over time, giving them tremendous flexibility and scalability to meet their changing business needs.

"The addition of BuzzeoPDMA truly makes First Source Sample the first and best place for pharmaceutical companies seeking a complete sample management solution," said Bill Buzzeo, now vice president and general manager of the BuzzeoPDMA division of Dendrite. "First Source Sample customers will now benefit from the single point of contact approach that can satisfy all sample promotion and management requirements, help ensure compliance with government regulations, execute with a lower cost, and attain a higher level of success."

Dendrite indicated that BuzzeoPDMA's 2004 revenue was an estimated $10 million. The all-cash transaction, valued at approximately $10 million, is expected to be neutral or slightly accretive in 2005.

About Dendrite

Dendrite is the first source for life science companies seeking expert, integrated global solutions to enhance the effectiveness of marketing, sales and clinical trial programs. For more information, visit www.dendrite.com. For more information on BuzzeoPDMA visit www.buzzeopdma.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.